Advancing the pathologic phenotype of giant axonal neuropathy: early involvement of the ocular lens

Diane Armao, Thomas W Bouldin, Rachel M Bailey, Jody E Hooper, Diana X Bharucha, Steven J Gray, Diane Armao, Thomas W Bouldin, Rachel M Bailey, Jody E Hooper, Diana X Bharucha, Steven J Gray

Abstract

Giant axonal neuropathy (GAN; ORPHA: 643; OMIM# 256850) is a rare, hereditary, pediatric neurodegenerative disorder associated with intracellular accumulations of intermediate filaments (IFs). GAN knockout (KO) mouse models mirror the IF dysregulation and widespread nervous system pathology seen in human GAN. Validation of therapeutic efficacy and viral vector delivery systems with these GAN KO models has provided the springboard for the development of a viral vector being delivered intrathecally in an ongoing Phase I gene therapy clinical trial for the treatment of children with GAN ( https://ichgcp.net/clinical-trials-registry/NCT02362438 ). During the course of a comprehensive pathologic characterization of the GAN KO mouse, we discovered the very early and unexpected involvement of the ocular lens. Light microscopy revealed the presence of intracytoplasmic inclusion bodies within lens epithelial cells. The inclusion bodies showed strong immunohistochemical positivity for glial fibrillary acidic protein (GFAP). We confirmed that intracytoplasmic inclusion bodies are also present within lens epithelial cells in human GAN. These IF inclusion bodies in lens epithelial cells are unique to GAN. Similar IF inclusion bodies in lens epithelial cells have not been reported previously in experimental animal models or human diseases. Since current paradigms in drug discovery and drug repurposing for IF-associated disorders are often hindered by lack of validated targets, our findings suggest that lens epithelial cells in the GAN KO mouse may provide a potential target, in vivo and in vitro, for evaluating drug efficacy and alternative therapeutic approaches in promoting the clearance of IF inclusions in GAN and other diseases characterized by intracellular IF accumulations.

Keywords: GAN KO mouse model; Giant axonal neuropathy (GAN); Gigaxonin; Human GAN; IF accumulations; Intermediate filaments (IF); Lens epithelium.

Conflict of interest statement

Ethics approval and consent to participate

All procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals [DHHS Publication No. (NIH) 85–23] and approved by the UNC–CH Institutional Animal Care and Use Committee. Human specimens were obtained through a validated autopsy consent from the legal next of kin, which explicitly stated that tissues could be used for research purposes. The consent and diagnostic autopsy report were filed in the deceased patient’s medical record.

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Ocular Lens. Control. Lens cells exist in two distinct forms, lens epithelial cells and lens fiber cells. The anterior surface of the lens is covered by a single layer of epithelial cells that serve as a reservoir for continual lens fiber cell formation and lens growth throughout life. The lens is unique as reflected in almost continuous cell production with negligible cell loss. On their path to becoming mature lens fiber cells, lens epithelial cells undergo extraordinary structural differentiation [10]. GAN KO mouse. Oval intracytoplasmic eosinophilic inclusion bodies within lens epithelial cells
Fig. 2
Fig. 2
Lens epithelial cells in GAN KO mice, age-matched controls and human GAN. a. GAN KO (4-month-old) lens epithelial cells show intracytoplasmic inclusion bodies (H&E original magnification 100X). b. GAN/J KO (24-month-old) lens epithelial cell inclusion bodies (H&E original magnification 100X). c. GAN/J KO (24-month-old) lens epithelial cell inclusion bodies show strong GFAP immunoreactivity (GFAP IHC original magnification 100X). d. Control mouse (24-month-old) histologically unremarkable lens epithelial cells (H&E original magnification 100X). e. Human GAN lens epithelial cells reveal intracytoplasmic inclusion bodies (H&E original magnification 100X, formalin fixed, paraffin embedded tissue. Decedent was a young child with phenotypically typical GAN) (arrows point to one of the numerous intracytoplasmic inclusion bodies). Inset. Lens epithelial cells. Control mouse (24-month-old) (H&E); GAN/J KO (24 -month-old) lens epithelial cell inclusion body (H&E); GAN/J KO (24-month-old) lens epithelial cell inclusion body shows strong GFAP immunoreactivity (GFAP IHC). (Ndesignates nucleus, arrow points to cytoplasmic inclusion body)

References

    1. Johnson-Kerner BL, Roth L, Greene JP, Wichterle H, Sproule DM. Giant axonal neuropathy: an updated perspective on its pathology and pathogenesis. Muscle Nerve. 2014;50(4):467–476. doi: 10.1002/mus.24321.
    1. Lin NH, Huang YS, Opal P, Goldman RD, Messing A, Perng MD. The role of gigaxonin in the degradation of the glial-specific intermediate filament protein GFAP. Mol Biol Cell. 2016;27(25):3980–3990. doi: 10.1091/mbc.e16-06-0362.
    1. Soomro A, Alsop RJ, Negishi A, Kreplak DF, Kuczmarski ER, Goldman RD, Rheinstadter MC. Giant axonal neuropathy alters the structure of keratin intermediate fialments in human hair. JR Soc Interface. 2017;14:1–9. doi: 10.1098/rsif.2017.0123.
    1. Ding J, Allen E, Wang W, Valle A, Wu C, Nardine T, et al. Gene targeting of GAN in mouse causes a toxic accumulation of microtubule-associated protein 8 and impaired retrograde axonal transport. Hum Mol Genet. 2006;15(9):1451–1463. doi: 10.1093/hmg/ddl069.
    1. Ganay T, Boizot A, Burrer R, Chauvin JP, Bomont P. Sensory-motor deficits and neurofilament disorganization in gigaxonin-null mice. Mol Neurodegener. 2011;6(1):25. doi: 10.1186/1750-1326-6-25.
    1. Dequen F, Bomont P, Gowing G, Cleveland DW, Julien J-P. Modest loss of peripheral axons, muscle atrophy and formation of brain inclusions in mice with targeted deletion of gigaxonin exon 1. J Neurochem. 2008;107(1):253–264. doi: 10.1111/j.1471-4159.2008.05601.x.
    1. Armao D, Bailey RM, Bouldin TW, Kim Y, Gray SJ. Autonomic nervous system involvement in the giant axonal neuropathy (GAN) KO mouse: implications for human disease. Clin Auton Res. 2016;26(4):307–313. doi: 10.1007/s10286-016-0365-7.
    1. Bailey RM, Armao D, Nagabhushan Kalburgi S, Gray SJ. Development of intrathecal AAV9 gene therapy for Giant axonal neuropathy. Mol Ther Methods Clin Dev. 2018;9:160–171. doi: 10.1016/j.omtm.2018.02.005.
    1. Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy [updated July 16, 2018. Available from: .
    1. Song S, Landsbury A, Dahm R, Liu Y, Zhang Q, Quinlan RA. Functions of the intermediate filament cytoskeleton in the eye lens. J Clin Invest. 2009;119(7):1837–1848. doi: 10.1172/JCI38277.
    1. Wolf NS, Li Y, Pendergrass W, Schmeider C, Turturro A. Normal mouse and rat strains as models for age-related cataract and the effect of caloric restriction on its development. Exp Eye Res. 2000;70(5):683–692. doi: 10.1006/exer.2000.0835.
    1. Roth LA, Marra JD, LaMarca NH, Sproule DM. Measuring disease progression in giant axonal neuropathy: implications for clinical trial design. J Child Neurol. 2015;30(6):741–748. doi: 10.1177/0883073814542946.
    1. Kumar K, Barre P, Nigro M, Jones MZ. Giant axonal neuropathy: clinical, electrophysiologic, and neuropathologic features in two siblings. J Child Neurol. 1990;5(3):229–234. doi: 10.1177/088307389000500316.
    1. Kretzschmar HA, Berg BO, Davis RL. Giant axonal neuropathy. A neuropathological study. Acta Neuropathol. 1987;73(2):138–144. doi: 10.1007/BF00693779.
    1. Peiffer J, Schlote W, Bischoff A, Boltshauser E, Muller G. Generalized giant axonal neuropathy: a filament-forming disease of neuronal, endothelial, glial, and schwann cells in a patient without kinky hair. Acta Neuropathol. 1977;40(3):213–218. doi: 10.1007/BF00691956.
    1. Thomas C, Love S, Powell HC, Schultz P, Lampert PW. Giant axonal neuropathy: correlation of clinical findings with postmortem neuropathology. Ann Neurol. 1987;22(1):79–84. doi: 10.1002/ana.410220118.
    1. Horwitz J. Alpha-crystallin. Exp Eye Res. 2003;76:145–153. doi: 10.1016/S0014-4835(02)00278-6.
    1. Hagemann TL, Boelens WC, Wawrousek EF, Messing A. Supression of GFAP toxicity by alpha B-crystallin in mouse models of Alexander disease. Hum Mol Genet. 2009;18(7):1190–1199. doi: 10.1093/hmg/ddp013.
    1. Varma H. Drug screening for Huntington's disease and other neurodegenerative disorders. Curr Mol Pharmacol. 2010;3(3):164–173. doi: 10.2174/1874467211003030164.
    1. Sun W, Zheng W, Simeonov A. Drug discovery and development for rare genetic disorders. Am J Med Genet A. 2017;173(9):2307–2322. doi: 10.1002/ajmg.a.38326.
    1. Martinez G, de Iongh RU. The lens epithelium in ocular health and disease. Int J Biochem Cell Biol. 2010;42(12):1945–1963. doi: 10.1016/j.biocel.2010.09.012.
    1. Snider NT, Omary MB. Post-translational modifications of intermediate filament proteins: mechanisms and functions. Nat Rev Mol Cell Biol. 2014;15(3):163–177. doi: 10.1038/nrm3753.

Source: PubMed

3
구독하다